-
Je něco špatně v tomto záznamu ?
Outcome measurement in functional neurological disorder: a systematic review and recommendations
S. Pick, DG. Anderson, AA. Asadi-Pooya, S. Aybek, G. Baslet, BR. Bloem, A. Bradley-Westguard, RJ. Brown, AJ. Carson, T. Chalder, M. Damianova, AS. David, MJ. Edwards, SA. Epstein, AJ. Espay, B. Garcin, LH. Goldstein, M. Hallett, J. Jankovic, EM....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, systematický přehled
Grantová podpora
CS-2014-14-016
Department of Health - United Kingdom
K23 NS045902
NINDS NIH HHS - United States
NV16-29651A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
ProQuest Central
od 1944-07-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1944-07-01 do Před 6 měsíci
Psychology Database (ProQuest)
od 1944-07-01 do Před 6 měsíci
PubMed
32111637
DOI
10.1136/jnnp-2019-322180
Knihovny.cz E-zdroje
- MeSH
- hodnocení výsledků zdravotní péče * MeSH
- lidé MeSH
- nemoci nervového systému diagnóza terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
OBJECTIVES: We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and to guide future research on FND outcomes. METHODS: A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, MEDLINE and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group. RESULTS: Five FND-specific measures were identified-three clinician-rated and two patient-rated-but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (ie, quality of life, disability and general functioning) and health economics/cost-utility (eg, healthcare resource use and quality-adjusted life years). CONCLUSIONS: There are few well-validated FND-specific outcome measures. Thus, at present, we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.
Academic Neurology Unit University of Sheffield Royal Hallamshire Hospital Sheffield UK
Department of Neurological Sciences Rush University Medical Center Chicago Illinois USA
Department of Neurology Feinberg School of Medicine Northwestern University Chicago Illinois USA
Department of Neurology Medical University of Graz Graz Austria
Department of Neurology University Hospital Bern and University of Bern Bern Switzerland
Department of Neuroscience Biomedicine and Movement University of Verona Verona Italy
Department of Psychiatry Austin Health University of Melbourne Melbourne Victoria Australia
Department of Psychiatry Georgetown University Washington District of Columbia USA
Departments of Psychiatry and Neurology Rhode Island Hospital Brown Medical School Providence RI USA
Donald Gordon Medical Centre University of the Witwatersrand Johannesburg South Africa
FND Hope International Salmon Idaho USA
Institute of Psychiatry Psychology and Neuroscience King's College London London UK
Mater Neurosciences Centre Brisbane Queensland Australia
Northeast Regional Epilepsy Group New York New York USA
School of Health Sciences The University of Manchester Manchester UK
Therapy Services The National Hospital for Neurology and Neurosurgery London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028133
- 003
- CZ-PrNML
- 005
- 20210114153043.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/jnnp-2019-322180 $2 doi
- 035 __
- $a (PubMed)32111637
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pick, Susannah $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 245 10
- $a Outcome measurement in functional neurological disorder: a systematic review and recommendations / $c S. Pick, DG. Anderson, AA. Asadi-Pooya, S. Aybek, G. Baslet, BR. Bloem, A. Bradley-Westguard, RJ. Brown, AJ. Carson, T. Chalder, M. Damianova, AS. David, MJ. Edwards, SA. Epstein, AJ. Espay, B. Garcin, LH. Goldstein, M. Hallett, J. Jankovic, EM. Joyce, RA. Kanaan, RC. Keynejad, K. Kozlowska, K. LaFaver, WC. LaFrance, AE. Lang, A. Lehn, S. Lidstone, CW. Maurer, B. Mildon, F. Morgante, L. Myers, C. Nicholson, G. Nielsen, DL. Perez, S. Popkirov, M. Reuber, KS. Rommelfanger, P. Schwingenshuh, T. Serranova, P. Shotbolt, GT. Stebbins, J. Stone, MA. Tijssen, M. Tinazzi, TR. Nicholson,
- 520 9_
- $a OBJECTIVES: We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and to guide future research on FND outcomes. METHODS: A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, MEDLINE and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group. RESULTS: Five FND-specific measures were identified-three clinician-rated and two patient-rated-but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (ie, quality of life, disability and general functioning) and health economics/cost-utility (eg, healthcare resource use and quality-adjusted life years). CONCLUSIONS: There are few well-validated FND-specific outcome measures. Thus, at present, we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nemoci nervového systému $x diagnóza $x terapie $7 D009422
- 650 12
- $a hodnocení výsledků zdravotní péče $7 D017063
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Anderson, David G $u Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.
- 700 1_
- $a Asadi-Pooya, Ali A $u Epilepsy Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of. Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- 700 1_
- $a Aybek, Selma $u Department of Neurology, University Hospital Bern & University of Bern, Bern, Switzerland.
- 700 1_
- $a Baslet, Gaston $u Department of Psychiatry, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- 700 1_
- $a Bloem, Bastiaan R $u Department of Neurology, Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands.
- 700 1_
- $a Bradley-Westguard, Abigail
- 700 1_
- $a Brown, Richard J $u School of Health Sciences, The University of Manchester, Manchester, UK.
- 700 1_
- $a Carson, Alan J $u Department of Clinical Neurosciences, School of Molecular and Clinical Medicine, Western General Hospital, University of Edinburgh, Edinburgh, UK.
- 700 1_
- $a Chalder, Trudie $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 700 1_
- $a Damianova, Maria $u Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.
- 700 1_
- $a David, Anthony S $u Institute of Mental Health, Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom.
- 700 1_
- $a Edwards, Mark J $u Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George's University, London, UK.
- 700 1_
- $a Epstein, Steven A $u Department of Psychiatry, Georgetown University, Washington, District of Columbia, USA.
- 700 1_
- $a Espay, Alberto J $u Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
- 700 1_
- $a Garcin, Béatrice $u Department of Neurology, Hopital Avicenne, Assistance Publique, Hôpitaux de Paris, Paris, Île-de-France, France.
- 700 1_
- $a Goldstein, Laura H $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 700 1_
- $a Hallett, Mark $u Human Motor Control Section, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
- 700 1_
- $a Jankovic, Joseph $u Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
- 700 1_
- $a Joyce, Eileen M $u University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
- 700 1_
- $a Kanaan, Richard A $u Department of Psychiatry, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.
- 700 1_
- $a Keynejad, Roxanne C $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 700 1_
- $a Kozlowska, Kasia $u Discipline of Psychiatry and Child and Adolescent Health, The Children's Hospital at Westmead, Sydney Medical School, Sydney, New South Wales, Australia.
- 700 1_
- $a LaFaver, Kathrin $u Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- 700 1_
- $a LaFrance, W Curt $u Departments of Psychiatry and Neurology, Rhode Island Hospital, Brown Medical School, Providence, RI, USA.
- 700 1_
- $a Lang, Anthony E $u Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, University Health Network, Toronto, Ontario, Canada.
- 700 1_
- $a Lehn, Alex $u Mater Neurosciences Centre, Brisbane, Queensland, Australia.
- 700 1_
- $a Lidstone, Sarah $u Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, University Health Network, Toronto, Ontario, Canada.
- 700 1_
- $a Maurer, Carine W $u Department of Neurology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.
- 700 1_
- $a Mildon, Bridget $u FND Hope International, Salmon, Idaho, USA.
- 700 1_
- $a Morgante, Francesca $u Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George's University, London, UK.
- 700 1_
- $a Myers, Lorna $u Northeast Regional Epilepsy Group, New York, New York, USA.
- 700 1_
- $a Nicholson, Clare $u Therapy Services, The National Hospital for Neurology and Neurosurgery, London, UK.
- 700 1_
- $a Nielsen, Glenn $u Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George's University, London, UK.
- 700 1_
- $a Perez, David L $u Departments of Neurology and Psychiatry, Therapy Services, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
- 700 1_
- $a Popkirov, Stoyan $u Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
- 700 1_
- $a Reuber, Markus $u Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK.
- 700 1_
- $a Rommelfanger, Karen S $u Departments of Neurology and Psychiatry and Behavioral Sciences, Emory Centre for Ethics, Emory University School of Medicine, Atlanta, Georgia, USA.
- 700 1_
- $a Schwingenshuh, Petra $u Department of Neurology, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Serranova, Tereza $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Shotbolt, Paul $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- 700 1_
- $a Stebbins, Glenn T $u Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
- 700 1_
- $a Stone, Jon $u Department of Clinical Neurosciences, School of Molecular and Clinical Medicine, Western General Hospital, University of Edinburgh, Edinburgh, UK.
- 700 1_
- $a Tijssen, Marina Aj $u Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Tinazzi, Michele $u Department of Neuroscience, Biomedicine, and Movement, University of Verona, Verona, Italy.
- 700 1_
- $a Nicholson, Timothy R $u Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK timothy.nicholson@kcl.ac.uk.
- 773 0_
- $w MED00010064 $t Journal of neurology, neurosurgery, and psychiatry $x 1468-330X $g Roč. 91, č. 6 (2020), s. 638-649
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32111637 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153040 $b ABA008
- 999 __
- $a ok $b bmc $g 1608468 $s 1119313
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 91 $c 6 $d 638-649 $e 20200228 $i 1468-330X $m Journal of neurology, neurosurgery and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
- GRA __
- $a CS-2014-14-016 $p Department of Health $2 United Kingdom
- GRA __
- $a K23 NS045902 $p NINDS NIH HHS $2 United States
- GRA __
- $a NV16-29651A $p MZ0
- LZP __
- $a Pubmed-20210105
